Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alibaba Group (BABA) vs Sanofi SA (SNY) Price & Performance

Alibaba GroupTrade

Price performance (Past 24H)

Key statistics

Alibaba Group vs Sanofi SA — how do they compare? Alibaba Group trades at $124.77 (market cap $309.65B), while Sanofi SA trades at $43.99 (market cap $104.57B). The key difference: Alibaba Group is far larger — about 3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.56%). Which is the better fit depends on your goals.

BABASNY
Market Cap
$309.65B$104.57B
Volume
18,069,938
Sector
Consumer CyclicalHealth
52-Week High
$189.34$52.34
52-Week Low
$94.83$41.33
Enterprise Value
$304.43B$124.48B
Dividend Yield
0.79%5.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alibaba Group

Alibaba (BABA) trades at $128.41, up 1.26% today, with a bullish technical signal and strong analyst support. Recent earnings misses contrast with solid fundamentals: revenue grew to $996.35B in 2025, net income margin expanded to 13.05%, and valuation ratios like P/E of 19.7 appear reasonable. The company announced a $1.05 dividend for H1-26 and faces multiple class-action lawsuits filed in August 2026, alleging securities fraud between June 2025 and June 2026.

Outlook is mixed: bullish analyst consensus (86% buy ratings) and a $195 price target suggest upside, but legal risks and earnings volatility pose headwinds. Investment opportunity hinges on AI growth and cloud strength, while risks include litigation outcomes and competitive pressures in China.

Sanofi SA

SNY trades at $43.46, up 1.33% today, with neutral technical signals and mixed analyst sentiment. The company reported strong Q2 2026 earnings beats and raised 2026 guidance, driven by Dupixent's performance. Recent approvals for MenQuadfi and Sarclisa injector provide growth catalysts, while pipeline setbacks like amlitelimab discontinuation present challenges. Valuation metrics show a P/E of 23.22 and P/S of 1.87, with improving profit margins from 12.55% in 2024 to 16.72% in 2025.

SNY offers steady dividend income with positive earnings momentum, though pipeline execution risks and competitive pressures remain concerns. The stock presents value for income-focused investors with upside potential from new drug approvals, but requires monitoring of CEO Garijo's strategic initiatives and Dupixent's long-term market position against biosimilar threats post-2031.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alibaba Group

Alibaba Group Holding Limited operates as a holding company. The Company provides internet infrastructure, electronic commerce, online financial, and internet content services through its subsidiaries. Alibaba Group Holding offers its products and services worldwide.

Read more on BABA

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY